Catabasis Pharmaceuticals (CATB) Q1 results: Revenues: $0; R&D Expense: $4.2M (-19.2%); SG&A: $2.1M (-12.5%); Net Loss: ($6M) (+22.1%); Loss Per Share: ($0.62) (+78.5%); Quick Assets: $51.7M (+37.5%); CF Ops (3M): ($6.6M) (+2.9%).
Top-line results from the Phase 3 PolarisDMD trial expected in H2 2020, commercial registration of edasalonexent expected in early 2021.
Shares are up 5% premarket in apparent response to the selloff in DMD competitor Solid Biosciences (-38% premarket) after it reported several adverse events in an early-stage study. Sarepta Therapeutics (NASDAQ:SRPT) is up 3% as well.
Previously: Catabasis Pharmaceuticals beats by $0.07 (May 14)
Subscribe for full text news in your inbox